Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $14.80 USD
Change Today +0.81 / 5.79%
Volume 617.5K
As of 4:00 PM 06/2/15 All times are local (Market data is delayed by at least 15 minutes).

invivo therapeutics holdings (NVIV) Snapshot

Open
$14.02
Previous Close
$13.99
Day High
$14.99
Day Low
$13.96
52 Week High
04/17/15 - $19.68
52 Week Low
09/10/14 - $1.86
Market Cap
393.1M
Average Volume 10 Days
266.2K
EPS TTM
$-1.07
Shares Outstanding
26.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for INVIVO THERAPEUTICS HOLDINGS (NVIV)

Related News

No related news articles were found.

invivo therapeutics holdings (NVIV) Related Businessweek News

No Related Businessweek News Found

invivo therapeutics holdings (NVIV) Details

Invivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, focuses on developing and commercializing technologies for the treatment of spinal cord injury (SCI). The company is developing a Neuro-Spinal Scaffold, an investigational bioresorbable polymer scaffold for the implantation at the site of injury within a spinal cord contusion; and biocompatible Neuro-Spinal Scaffold Plus Stem Cells to treat chronic SCI. Its proprietary technologies incorporate intellectual property licensed under exclusive, worldwide license from Boston Children's Hospital and the Massachusetts Institute of Technology, as well as intellectual property that has been developed internally in collaboration with advisors and partners. The company was founded in 2005 and is based in Cambridge, Massachusetts.

31 Employees
Last Reported Date: 03/11/15
Founded in 2005

invivo therapeutics holdings (NVIV) Top Compensated Officers

Chairman of the Board and Chief Executive Off...
Total Annual Compensation: $532.3K
Chief Financial Officer
Total Annual Compensation: $369.1K
Chief Compliance Officer, Senior Vice Preside...
Total Annual Compensation: $171.1K
Chief Scientific Officer
Total Annual Compensation: $253.7K
Compensation as of Fiscal Year 2014.

invivo therapeutics holdings (NVIV) Key Developments

InVivo Therapeutics Holdings Corp. Reports Update of First Two Spinal Cord Injury Patients Implanted with Neuro-Spinal Scaffold

InVivo Therapeutics Holdings Corp. announced a six-month post-implant update for the first study patient and a three-month post-implant update for the second study patient in the company’s ongoing pilot trial of its investigational Neuro-Spinal Scaffold in patients with acute spinal cord injury. The Neuro-Spinal Scaffold was implanted in the first patient in October 2014 at the Barrow Neurological Institute, Phoenix, AZ and in the second patient in January 2015 at the Carolinas Medical Center, Charlotte, NC. From the three-month assessment to the six-month assessment, the first patient has demonstrated continued improvement in motor function as assessed by the International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) exam. The patient has regained partial function of knee extensors and remains classified as ASIA Impairment Scale C (AIS C) with a motor incomplete spinal cord injury. The second patient remains classified as AIS A with a complete spinal cord injury. Of note is the appreciable improvement in the second patient’s trunk stability, self-care, mobility and bowel and bladder function at the three-month post-implant assessment. There have been no reported Adverse Events associated with the Neuro-Spinal Scaffold to date in either patient.

InVivo Therapeutics Holdings Corp. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015

InVivo Therapeutics Holdings Corp. reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter ended March 31, 2015, the Company reported a net loss of approximately $15,830,000 or $0.64 per diluted share, compared to a net loss of $5,103,000 or $0.28 per diluted share, for the quarter ended March 31, 2014. Operating loss was $5,511,000 compared to $5,071,000 a year ago. Non GAAP net loss was $15,544,000 compared to $5,103,000 for the quarter ended March 31, 2014. First quarter 2015 results were adversely impacted by a loss in the derivative warrant liability of $10,286,000. Excluding the impact of the derivative warrant liability, the earnings loss per diluted share for the quarters ended March 31, 2015 and 2014 were $0.22 and $0.28, respectively.

InVivo Therapeutics Holdings Corp. will Change its Ticker to NVIVD from NVIV

Effective April 08, 2015, InVivo Therapeutics Holdings Corp. will change its Pink Sheets LLC stock ticker symbol to NVIVD from NVIV.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NVIV:US $14.80 USD +0.81

NVIV Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for NVIV.
View Industry Companies
 

Industry Analysis

NVIV

Industry Average

Valuation NVIV Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 35.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INVIVO THERAPEUTICS HOLDINGS, please visit www.invivotherapeutics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.